Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole

32Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

Abstract

Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/ day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.

Cite

CITATION STYLE

APA

Fernández, M. L., Marson, M. E., Ramirez, J. C., Mastrantonio, G., Schijman, A. G., Altcheh, J., … Bournissen, F. G. (2016). Pharmacokinetic and pharmacodynamic responses in adult patients with chagas disease treated with a new formulation of benznidazole. Memorias Do Instituto Oswaldo Cruz, 111(3), 218–221. https://doi.org/10.1590/0074-02760150401

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free